|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FBXO22 |
Gene summary for FBXO22 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FBXO22 | Gene ID | 26263 |
| Gene name | F-box protein 22 | |
| Gene Alias | FBX22 | |
| Cytomap | 15q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q8NEZ5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26263 | FBXO22 | LZE2T | Human | Esophagus | ESCC | 6.79e-05 | 6.07e-01 | 0.082 |
| 26263 | FBXO22 | LZE4T | Human | Esophagus | ESCC | 9.72e-14 | 4.53e-01 | 0.0811 |
| 26263 | FBXO22 | LZE7T | Human | Esophagus | ESCC | 7.56e-11 | 6.41e-01 | 0.0667 |
| 26263 | FBXO22 | LZE8T | Human | Esophagus | ESCC | 1.27e-02 | 1.55e-01 | 0.067 |
| 26263 | FBXO22 | LZE22T | Human | Esophagus | ESCC | 9.82e-06 | 3.44e-01 | 0.068 |
| 26263 | FBXO22 | LZE24T | Human | Esophagus | ESCC | 1.65e-08 | 2.72e-01 | 0.0596 |
| 26263 | FBXO22 | LZE6T | Human | Esophagus | ESCC | 4.64e-07 | 3.65e-01 | 0.0845 |
| 26263 | FBXO22 | P1T-E | Human | Esophagus | ESCC | 3.98e-07 | 2.85e-01 | 0.0875 |
| 26263 | FBXO22 | P2T-E | Human | Esophagus | ESCC | 1.24e-24 | 4.55e-01 | 0.1177 |
| 26263 | FBXO22 | P4T-E | Human | Esophagus | ESCC | 4.08e-27 | 7.36e-01 | 0.1323 |
| 26263 | FBXO22 | P5T-E | Human | Esophagus | ESCC | 2.95e-14 | 3.11e-01 | 0.1327 |
| 26263 | FBXO22 | P8T-E | Human | Esophagus | ESCC | 6.00e-14 | 2.70e-01 | 0.0889 |
| 26263 | FBXO22 | P9T-E | Human | Esophagus | ESCC | 3.95e-15 | 4.60e-01 | 0.1131 |
| 26263 | FBXO22 | P10T-E | Human | Esophagus | ESCC | 9.54e-29 | 5.26e-01 | 0.116 |
| 26263 | FBXO22 | P11T-E | Human | Esophagus | ESCC | 4.46e-05 | 2.35e-01 | 0.1426 |
| 26263 | FBXO22 | P12T-E | Human | Esophagus | ESCC | 7.67e-20 | 4.20e-01 | 0.1122 |
| 26263 | FBXO22 | P15T-E | Human | Esophagus | ESCC | 3.42e-30 | 6.33e-01 | 0.1149 |
| 26263 | FBXO22 | P16T-E | Human | Esophagus | ESCC | 3.32e-31 | 6.15e-01 | 0.1153 |
| 26263 | FBXO22 | P19T-E | Human | Esophagus | ESCC | 1.48e-12 | 7.90e-01 | 0.1662 |
| 26263 | FBXO22 | P20T-E | Human | Esophagus | ESCC | 1.48e-25 | 5.11e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:0042176111 | Esophagus | ESCC | regulation of protein catabolic process | 280/8552 | 391/18723 | 8.65e-26 | 2.39e-23 | 280 |
| GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
| GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
| GO:1903362111 | Esophagus | ESCC | regulation of cellular protein catabolic process | 188/8552 | 255/18723 | 5.12e-20 | 6.62e-18 | 188 |
| GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
| GO:1903050111 | Esophagus | ESCC | regulation of proteolysis involved in cellular protein catabolic process | 163/8552 | 221/18723 | 1.44e-17 | 1.27e-15 | 163 |
| GO:0061136111 | Esophagus | ESCC | regulation of proteasomal protein catabolic process | 142/8552 | 187/18723 | 2.40e-17 | 2.00e-15 | 142 |
| GO:000020917 | Esophagus | ESCC | protein polyubiquitination | 170/8552 | 236/18723 | 1.40e-16 | 1.09e-14 | 170 |
| GO:0045732111 | Esophagus | ESCC | positive regulation of protein catabolic process | 167/8552 | 231/18723 | 1.47e-16 | 1.14e-14 | 167 |
| GO:0032434111 | Esophagus | ESCC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 107/8552 | 134/18723 | 4.06e-16 | 2.93e-14 | 107 |
| GO:2000058111 | Esophagus | ESCC | regulation of ubiquitin-dependent protein catabolic process | 125/8552 | 164/18723 | 1.17e-15 | 7.76e-14 | 125 |
| GO:1903364111 | Esophagus | ESCC | positive regulation of cellular protein catabolic process | 117/8552 | 155/18723 | 3.25e-14 | 1.66e-12 | 117 |
| GO:1901800110 | Esophagus | ESCC | positive regulation of proteasomal protein catabolic process | 91/8552 | 114/18723 | 6.74e-14 | 3.34e-12 | 91 |
| GO:1903052110 | Esophagus | ESCC | positive regulation of proteolysis involved in cellular protein catabolic process | 101/8552 | 133/18723 | 9.58e-13 | 4.19e-11 | 101 |
| GO:0032436111 | Esophagus | ESCC | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 72/8552 | 90/18723 | 2.30e-11 | 7.87e-10 | 72 |
| GO:2000060111 | Esophagus | ESCC | positive regulation of ubiquitin-dependent protein catabolic process | 81/8552 | 107/18723 | 2.23e-10 | 6.34e-09 | 81 |
| GO:006053716 | Esophagus | ESCC | muscle tissue development | 211/8552 | 403/18723 | 3.84e-03 | 1.56e-02 | 211 |
| GO:001470615 | Esophagus | ESCC | striated muscle tissue development | 197/8552 | 384/18723 | 1.46e-02 | 4.74e-02 | 197 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa0513214 | Liver | NAFLD | Salmonella infection | 55/1043 | 249/8465 | 8.48e-06 | 3.09e-04 | 2.49e-04 | 55 |
| hsa0513215 | Liver | NAFLD | Salmonella infection | 55/1043 | 249/8465 | 8.48e-06 | 3.09e-04 | 2.49e-04 | 55 |
| hsa0513242 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
| hsa0513252 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
| hsa0513230 | Oral cavity | OSCC | Salmonella infection | 174/3704 | 249/8465 | 2.67e-17 | 1.49e-15 | 7.58e-16 | 174 |
| hsa05132114 | Oral cavity | OSCC | Salmonella infection | 174/3704 | 249/8465 | 2.67e-17 | 1.49e-15 | 7.58e-16 | 174 |
| hsa05132210 | Oral cavity | LP | Salmonella infection | 128/2418 | 249/8465 | 1.17e-14 | 2.79e-13 | 1.80e-13 | 128 |
| hsa0513238 | Oral cavity | LP | Salmonella infection | 128/2418 | 249/8465 | 1.17e-14 | 2.79e-13 | 1.80e-13 | 128 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FBXO22 | SNV | Missense_Mutation | c.154N>C | p.Trp52Arg | p.W52R | Q8NEZ5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
| FBXO22 | SNV | Missense_Mutation | novel | c.428N>C | p.Cys143Ser | p.C143S | Q8NEZ5 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FBXO22 | SNV | Missense_Mutation | c.469N>G | p.Pro157Ala | p.P157A | Q8NEZ5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FU-A3HY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FBXO22 | SNV | Missense_Mutation | novel | c.1013G>A | p.Gly338Glu | p.G338E | Q8NEZ5 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| FBXO22 | SNV | Missense_Mutation | c.608G>T | p.Arg203Ile | p.R203I | Q8NEZ5 | protein_coding | tolerated(0.08) | benign(0.047) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| FBXO22 | SNV | Missense_Mutation | c.983G>T | p.Gly328Val | p.G328V | Q8NEZ5 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| FBXO22 | SNV | Missense_Mutation | c.1099N>T | p.Arg367Trp | p.R367W | Q8NEZ5 | protein_coding | deleterious(0) | benign(0.031) | TCGA-AA-A01T-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| FBXO22 | SNV | Missense_Mutation | c.377N>T | p.Arg126Ile | p.R126I | Q8NEZ5 | protein_coding | deleterious(0) | possibly_damaging(0.809) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| FBXO22 | SNV | Missense_Mutation | c.1183G>A | p.Ala395Thr | p.A395T | Q8NEZ5 | protein_coding | tolerated(1) | benign(0) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FBXO22 | SNV | Missense_Mutation | c.104C>T | p.Thr35Ile | p.T35I | Q8NEZ5 | protein_coding | tolerated(0.08) | benign(0.121) | TCGA-G4-6310-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fu | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |